19 results
8-K/A
SLRN
Acelyrin Inc
28 May 24
Departure of Directors or Certain Officers
5:20pm
at Zymergen, Inc., a biotechnology company. Previously, she also served as the Senior Vice President of Corporate Strategy and General Counsel of Atara
8-K
EX-99.1
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
milestones.
“Our top priority is executing on our strategy to accelerate the development and delivery of transformative medicines for patients, and we … suppurativa program, which will help inform our strategy. Given the capital intensity required to fully develop izokibep in multiple indications, we
8-K
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
of Corporate Development at Zymergen, Inc., a biotechnology company. Previously, she also served as the Senior Vice President of Corporate Strategy
DEF 14A
SLRN
Acelyrin Inc
22 Apr 24
Definitive proxy
4:10pm
biopharmaceutical company, since July 2023. Mr. Gosebruch served as executive vice president and chief strategy officer at AbbVie Inc., a global publicly traded … biopharmaceutical company, from December 2015 to February 2023. As a member of AbbVie’s Executive Team, he was responsible for corporate strategy
10-K
t1d13hx
28 Mar 24
Annual report
4:21pm
10-Q
ibohjivl1 ea
15 Jun 23
Quarterly report
4:19pm
424B4
dzme1nf
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
njg b5fn113xuln
1 May 23
IPO registration (amended)
6:10am
CORRESP
s0bzb rj63
20 Apr 23
Correspondence with SEC
12:00am
S-1
EX-4.2
58z7 28b2io
13 Apr 23
IPO registration
5:10pm
S-1
EX-3.1
0nypshagdo8sat
13 Apr 23
IPO registration
5:10pm
S-1
EX-10.12
4ja8c5wv76bzza
13 Apr 23
IPO registration
5:10pm
S-1
EX-10.13
4y2phhx w8
13 Apr 23
IPO registration
5:10pm
S-1
EX-2.1
l36xynk ubg03ptt35
13 Apr 23
IPO registration
5:10pm
S-1
ih8bc ozr
13 Apr 23
IPO registration
5:10pm
- Prev
- 1
- Next